Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review

J Am Acad Dermatol. 2019 Jul;81(1):265-267. doi: 10.1016/j.jaad.2018.12.017. Epub 2018 Dec 15.

Authors

Rachel G Casseres¹, Jared S Kahn¹, Min Ji Her², David Rosmarin³

Affiliations

¹ Tufts University School of Medicine, Boston, Massachusetts; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.
² Tufts University School of Medicine, Boston, Massachusetts.
³ Tufts University School of Medicine, Boston, Massachusetts; Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. Electronic address: drosmarin@tuftsmedicalcenter.org.

PMID: 30562567
DOI: 10.1016/j.jaad.2018.12.017

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Cohort Studies
Drug Approval*
Female
Follow-Up Studies
Hidradenitis Suppurativa / diagnosis*
Hidradenitis Suppurativa / drug therapy*
Humans
Injections, Subcutaneous
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Treatment Outcome
United States
United States Food and Drug Administration
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
guselkumab